TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2862814
Drug: Orciprenaline 10
Normalized name: Orciprenaline 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orciprenaline 10 mg
Study: 2862814
Drug: Prenalterol 10
Normalized name: prenalterol
DrugBank: Prenalterol (DB13777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenalterol 10 mg
Study: 29873684
Drug: Oxaliplatin added
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin added to 5-FU-based chemoradiotherapy and adjuvant chemotherapy in patients aged <60 years
Study: 29873684
Drug: Oxaliplatin added
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin added to 5-FU-based chemoradiotherapy and adjuvant chemotherapy in patients aged 40-70 years
Study: 19393850
Drug: Test product
Normalized name: Patch test product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test product (Integrol(R)) 10 mg tablet
Study: 19393850
Drug: Reference product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference product (Zyprexa(R)) 10 mg tablet
Study: 15325831
Drug: non-steroidal anti-inflammatory
Normalized name: Non-steroidal anti-inflammatory agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-steroidal anti-inflammatory drugs (naproxen 500 mg twice daily or ibuprofen 800 mg three times daily)
Study: 15325831
Drug: non-steroidal anti-inflammatory
Normalized name: Non-steroidal anti-inflammatory agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-steroidal anti-inflammatory drugs
Study: 11215327
Drug: Controlled release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled release dihydrocodeine (DHC) 60 mg
Study: 11215327
Drug: Controlled release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled release dihydrocodeine (DHC) 120 mg
Study: 16756423
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg diazepam
Study: 30592963
Drug: FOLFOX-6 regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX-6 regimen with L-carnosine (500 mg daily)
Study: 30592963
Drug: FOLFOX-6 regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX-6 regimen without L-carnosine
Study: 28477428
Drug: ivacaftor 150
Normalized name: ivacaftor 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivacaftor 150 mg alone (study A)
Study: 28477428
Drug: ivacaftor 150
Normalized name: ivacaftor 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivacaftor 150 mg plus ritonavir 50 mg daily (study B)
Study: 28477428
Drug: ivacaftor 150
Normalized name: ivacaftor 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivacaftor 150 mg plus ritonavir 50 mg daily after two weeks of ritonavir 50 mg daily (study C)
Study: 21667097
Drug: Overall follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall follow-up after ablative treatment
Study: 16131698
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation (500 or 1000 mg/d for 2 weeks)
Study: 7666815
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) - either peroral or transdermal 17‐beta‐oestradiol with cyclic addition of dydrogesterone or 2.5 mg Tibolone (Org OD 14) in a daily peroral dose
Study: 326302
Drug: Atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50 mg) and Acetazolamide (500 mg) in combination
Study: 326302
Drug: Vehicle (inert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (inert tablets)
Study: 27866187
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein supplementation (24 g PRO)
Study: 27866187
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein plus creatine supplementation (24 g PRO + 5 g creatine)
Study: 22944053
Drug: tianmaixiaoke tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: tianmaixiaoke tablet 240 mg bid for 24 weeks
Study: 22944053
Drug: sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: sitagliptin 100 mg qd for 24 weeks
Study: 16417772
Drug: Qingqiao Capsule
DrugBank: Forsythia suspensa fruit (DB14345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qingqiao Capsule (QQC), 5 capsules each time, 3 times a day for 10-14 days
Study: 16417772
Drug: Cefaclor capsules,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor capsules, 0.5 g each time for adults, 3 times a day, or 20 mg/(kg.d) for children, for 10-14 days
Study: 16417772
Drug: Qingqiao Capsule
DrugBank: Forsythia suspensa fruit (DB14345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qingqiao Capsule (QQC)
Study: 16417772
Drug: Cefaclor capsules
Normalized name: Cefaclor Capsules
DrugBank: Cefaclor (DB00833)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefaclor capsules
Study: 12854076
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CM235 and SF2 gp120 vaccines
Study: 2016618
Drug: Chlorambucil (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorambucil (30 mg/m2 orally day 1) and Prednisone (80 mg orally days 1 to 5) administered every 2 weeks (C + P)
Study: 2016618
Drug: Cyclophosphamide (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (300 mg/m2 orally days 1 to 5), Vincristine (1.4 mg/m2 intravenously [IV] day 1), and Prednisone (100 mg/m2 orally days 1 to 5) given every 3 weeks (CVP)
Study: 31810741
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no periodontal treatment)
Study: 29912799
Drug: Aripiprazole (5-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (5-15 mg/d)
Study: 27344828
Drug: Float needle
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Float needle therapy combined with reperfusion activity
Study: 27344828
Drug: Simple float
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple float needle therapy
Study: 24939425
Drug: Coinfusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coinfusion of low-dose GLP-1 and glucagon
Study: 17561350
Drug: Taxane treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxane treatment arm
Study: 16205932
Drug: Choline-stabilized orthosilicic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline-stabilized orthosilicic acid (ch-OSA) 10 mg Si/day for 20 weeks
Study: 12885182
Drug: Fentanyl 50
Normalized name: fentanyl 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 50 mcg/kg (group F)
Study: 12885182
Drug: Fentanyl 10
Normalized name: FENTANYL 100MCG/HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 10 mcg/kg plus etomidate 0.2 mg/kg (group EF)
Study: 9322520
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of lamivudine
Study: 9322520
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg of lamivudine
Study: 8135383
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine topical solution
Study: 105441
Drug: Superfractionation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Superfractionation treatment
Study: 28752209
Drug: Extended-release nicotinic
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended-release nicotinic acid (ERN) 2 g/day for 8 weeks
Study: 22035508
Drug: High-dose pirfenidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose pirfenidone (1800 mg/day)
Study: 22035508
Drug: Low-dose pirfenidone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose pirfenidone (1200 mg/day)
Study: 16735334
Drug: Curtains treated
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Curtains treated with lambdacyhalothrin and water treatment with pyriproxyfen chips in Veracruz
Study: 15332694
Drug: Pharmacist surveillance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist surveillance for adverse drug events (ADEs)
Study: 15332694
Drug: Pharmacist surveillance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist surveillance for drug classes associated with ADEs
Study: 9283534
Drug: Nocturnal CPAP
Normalized name: Nocdurna
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nocturnal CPAP plus optimal medical therapy (n = 9)
Study: 9283534
Drug: Optimal medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical therapy alone (n = 8)
Study: 3324520
Drug: Febuprol (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuprol (3 X 200 mg t. i. d.)
Study: 28862770
Drug: Oral glucosamine
Normalized name: glucosamine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucosamine (GS) + hyaluronic acid (HA) injection
Study: 28862770
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo + hyaluronic acid (HA) injection
Study: 26777773
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT) as an adjunct to usual care (medication)
Study: 26777773
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (medication)
Study: 22553931
Drug: l-arginine (6.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-arginine (6.4 g/day)
Study: 18008242
Drug: Sulfadoxine‐pyrimethamine (SP;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine‐pyrimethamine (SP; 250 and 12.5 mg)
Study: 16166818
Drug: 300 ml
Normalized name: HYQVIA 30 GM / 300 ML Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 ml wine from one of four different grapes and fermentation processes
Study: 10907623
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg magnesium citrate twice daily for 1 month
Study: 6208750
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (cis-platinum, bleomycin, and vinblastine)
Study: 6208750
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus irradiation
Study: 28143529
Drug: Individualized, computerized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized, computerized patient decision-aid for immunosuppressive drugs
Study: 28143529
Drug: Standard pamphlet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pamphlet with information about lupus and its treatment
Study: 25932553
Drug: Emixustat (2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emixustat (2, 5, 7, or 10 mg once daily)
Study: 23545911
Drug: Extended-release 45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release 45 mg oral minocycline
Study: 23545911
Drug: Extended-release 45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release 45 mg oral minocycline plus 15% azelaic acid
Study: 18226251
Drug: Inhaled corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroid use
Study: 16413877
Drug: Iron (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron (12.5 mg) and folic acid (50 mug)
Study: 12409968
Drug: MCG QRS‐T
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCG QRS‐T area integrals and QRS‐T angle in magnetic field maps
Study: 9825256
Drug: New topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: New topical therapies
Study: 9825256
Drug: New treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: New treatments that control IOP effectively over time
Study: 7907677
Drug: Warfarin (prothrombin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (prothrombin time ratio 1.3‐1.8, international normalised ratio 2.0‐4.5)
Study: 2811069
Drug: Nitrendipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (20 mg) administered twice daily for five days
Study: 2811069
Drug: Bumetanide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bumetanide (1 mg, i.v.) administered for the last three days of each period
Study: 2811069
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered twice daily for five days
Study: 4037
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg terbutaline sulfate (beta‐adrenoceptor stimulating compound)
Study: 10085709
Drug: Hemodialysis treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemodialysis treatment
Study: 29752828
Drug: Cigarettes containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cigarettes containing 20 mg of THC
Study: 27032659
Drug: Person-centered treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Person-centered treatment planning (Control)
Study: 24365986
Drug: Tac (twice-daily)
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tac (twice-daily)
Study: 24365986
Drug: TacMR (once-daily)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TacMR (once-daily)
Study: 24365986
Drug: Tac (twice-daily)
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tac (twice-daily) after switching back
Study: 20584695
Drug: Self-prescribed decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-prescribed decoction eliminating herpes combined with recombinant IL-2 and valaciclovir hydrochloride tablets
Study: 20584695
Drug: Recombinant IL-2
Normalized name: Human il-12 (recombinant)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant IL-2 and valaciclovir hydrochloride tablets
Study: 18676527
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of American ginseng extract
Study: 18676527
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of American ginseng extract
Study: 12971959
Drug: Prophylactic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic therapy (specifics not detailed)
Study: 12971959
Drug: No prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prophylactic therapy (control group)
Study: 10395842
Drug: Canarypox vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canarypox vaccine expressing multiple HIV-1 genes given alone or with rgp120
Study: 10395842
Drug: Canarypox vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canarypox vaccine expressing multiple HIV-1 genes given with rgp120
Study: 8618110
Drug: Cefetamet-pivoxil (CET,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefetamet-pivoxil (CET, 500 mg BID)
Study: 8618110
Drug: Cefixime (CFX,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime (CFX, 400 mg qD)
Study: 8618110
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil (CA, 250 mg BID)
Study: 2405523
Drug: Cefmetazole (CM)
Normalized name: Cefmetazole
DrugBank: Cefmetazole (DB00274)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefmetazole (CM) 1 gram IV every 8 hours for 3 doses starting 30 minutes before surgery
Study: 2405523
Drug: Cefoxitin (CX)
DrugBank: Cefoxitin (DB01331)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefoxitin (CX) 2 grams IV every 6 hours for 3 doses
Study: 23110444
Drug: Ibuprofen foam
Normalized name: ibuprofen Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen foam dressing
Study: 23110444
Drug: Comparator foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator foam dressing without ibuprofen
Study: 20504911
Drug: Valsartan (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (240 to 320 mg.day(‐1))
Study: 20504911
Drug: Bradykinin B2-type
Normalized name: adenovirus, type 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bradykinin B2-type receptor antagonist icatibant (50 mug.kg(‐1))
Study: 17646507
Drug: Liberal fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal fluid management (median 4250 mL, range 3150-5200 mL)
Study: 17646507
Drug: Restrictive fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive fluid management (median 1740 mL, range 1100-2165 mL)
Study: 15810473
Drug: Oral-B CrossAction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-B CrossAction Vitalizer toothbrush
Study: 11763941
Drug: Oral-B CrossAction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-B CrossAction toothbrush
Study: 15810473
Drug: Oral-B Advantage
Normalized name: Advantage Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-B Advantage toothbrush
Study: 6110088
Drug: Vaccine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine (3 monthly injections)
Study: 6110088
Drug: Placebo (corresponding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (corresponding injections)
Study: 26368296
Drug: Mesalamine granules
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesalamine granules 1.5 g once daily for 6 months
Study: 20930279
Drug: High-dose phenserine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose phenserine (10 and 15 mg BID)
Study: 20930279
Drug: High-dose phenserine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose phenserine (more than 12 weeks)
Study: 20930279
Drug: High-dose phenserine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose phenserine (after 12 weeks)
Study: 16361622
Drug: Docetaxel 85
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 85 mg/m2 on day 8 plus gemcitabine 800 mg/m2 on days 1 and 8 (arm A)
Study: 16361622
Drug: Docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m2 on day 1 plus cisplatin 75 mg/m2 on day 1 (arm B)
Study: 10379016
Drug: Soybean oil
Normalized name: Soybean Oil
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soybean oil diet (0.5 g trans fatty acid per 100 g)
Study: 10379016
Drug: Semiliquid margarine
Normalized name: MARGARINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semiliquid margarine diet (0.5 g trans fatty acid per 100 g)
Study: 10379016
Drug: Soft margarine
Normalized name: Soft margarine not polyunsaturated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft margarine diet (7.4 g trans fatty acid per 100 g)
Study: 10379016
Drug: Shortening diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shortening diet (9.9 g trans fatty acid per 100 g)
Study: 10379016
Drug: Stick margarine
Normalized name: Zit Stick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stick margarine diet (20.1 g trans fatty acid per 100 g)
Study: 2436423
Drug: 1% 11a-hydroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% 11a-hydroxyprogesterone lotion
Study: 31721143
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg oral micronized progesterone, six-hourly, starting at 14-18 weeks
Study: 25342408
Drug: Doppler-guided goal-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doppler-guided goal-directed fluid therapy
Study: 20576734
Drug: Intensive communication
Normalized name: cocklebur pollen extract
DrugBank: Xanthium strumarium pollen (DB10356)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive communication system (ICS) with family meetings within 5 days of ICU admission and weekly thereafter
Study: 18004131
Drug: GHB (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHB (40 or 60 mg/kg)
Study: 12062456
Drug: Amantadine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine (100 mg bid)
Study: 10202741
Drug: Transdermal 17-beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17-beta estradiol 50 micrograms/d
Study: 10202741
Drug: Ossein-hydroxyapatite compound
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ossein-hydroxyapatite compound 3.32 g/d
Study: 10202741
Drug: Transdermal 17-beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17-beta estradiol 50 micrograms/d plus Ossein-hydroxyapatite compound 3.32 g/d
Study: 1771100
Drug: Etozolin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etozolin (200 mg, 400 mg, 600 mg)
Study: 1771100
Drug: Chlorthalidone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone (25 mg, 50 mg, 75 mg)
Study: 9007884
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (10 mg)
Study: 17619868
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine (10 mg)
Study: 24916838
Drug: Subcutaneous (SQ)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SQ) insulin
Study: 23350696
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) insulin
Study: 21457235
Drug: MAP0004 (0.63
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAP0004 (0.63 mg emitted dose; 1.0 mg nominal dose)
Study: 17359519
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional therapy (Group C)
Study: 11511435
Drug: Cardiac resynchronisation
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronisation therapy (atrio-bi-ventricular)
Study: 11511435
Drug: Control (optimal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (optimal medical therapy with diuretics, ACE inhibitors, and beta-blockers)
Study: 9612361
Drug: Drug-free treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-free treatment (Control)
Study: 2694740
Drug: Gestrinone (2.5-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gestrinone (2.5-5 mg, orally or by vaginal pessary, two or three times weekly)
Study: 17603225
Drug: Glimepiride 2
Normalized name: glimepiride 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride 2 mg once-daily
Study: 17603225
Drug: Glimepiride 1
Normalized name: glimepiride 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride 1 mg twice-daily
Study: 17603225
Drug: Glimepiride 2
Normalized name: glimepiride 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride 2 mg once-daily and 1 mg twice-daily
Study: 3075109
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg twice a day for 5 weeks)